Managing Asthma Patients With AMAZE™: A Novel Disease Management Platform

Not Applicable

Completed

Conditions: Asthma

Interventions: Device: AMAZE™ Application
Device: AMAZE™ Dashboard

Registration Number: NCT04868500

Lead Sponsor: AstraZeneca

Brief Summary: The primary study objective is to generate evidence as to the feasibility, usability, perceived value, and potential benefits of implementing the AMAZE™ platform into clinical practice.

Detailed Description: AstraZeneca has developed the AMAZE™ disease management platform to be used across multiple disease indications to provide a unified experience for the management of participants throughout their participant care journey. AMAZE™ integrates multiple systems, including a patient mobile application where patients can enter daily symptoms and impact to communicate this information to their healthcare provider, as well as access disease educational materials. Implementation of AMAZE™ within clinical practice has not yet been evaluated. The results from this study will be used to inform any changes or modifications that need to be made to the technology platform, its implementation process, and explore impact on clinical outcomes.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 49

Inclusion Criteria

>18 years of age at the time of enrollment
Clinically confirmed diagnosis of asthma
Access to a smartphone with internet access with the following requirements: iOS (Operating System iOS 13 or newer and Devices iPhone 8 or newer) or Android (Operating System 8.0 or newer)
Able to understand and speak English sufficiently to be able to use the AMAZE™ patient app
Willingness to participate in a telephone interview and be audio-recorded
Consenting to participate in the study

Exclusion Criteria

Current diagnosis of active chronic obstructive pulmonary disease (COPD) or any pulmonary diagnosis other than asthma
Has a cognitive impairment, hearing difficulty, acute psychopathology, medical condition, or insufficient knowledge of the English language that, in the opinion of the investigator, would interfere with his or her ability to agree to participate and/or complete the ACT™.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Massachusetts General Hospital (MGH) Participants	AMAZE™ Application	Participants will use the AMAZE™ application to enter daily asthma symptoms and impact to communicate this information to their healthcare provider, as well as access disease educational materials up to six months.
Massachusetts General Hospital (MGH) Clinical Site Staff	AMAZE™ Dashboard	Clinical site staff will use the AMAZE™ dashboard for six months to identify usability and barriers, benefits, challenges, ease of implementation, and areas for improvement of the AMAZE™ dashboard in a clinical setting.

Primary Outcome Measures

Name	Time	Method
Number of Days Participants Accessed the AMAZE™ App (Weeks 1 to 4)	Weeks 1 to 4	Participant App usage was measured as the number of days the participant engaged (ie., participants accessed 'Home, Daily asthma log, Air quality, My plan, Trends, Appointments, Educational material, Messages, and Notifications') with the App during Weeks 1 to 4.
Number of Days Participants Accessed the AMAZE™ App (Weeks 5 to 8)	Weeks 5 to 8	Participant App usage was measured as the number of days the participant engaged (ie., participants accessed 'Home, Daily asthma log, Air quality, My plan, Trends, Appointments, Educational material, Messages, and Notifications') with the App during Weeks 5 to 8.
Number of Days Participants Accessed the AMAZE™ App (Weeks 9 to 12)	Weeks 9 to 12	Participant App usage was measured as the number of days the participant engaged (ie., participants accessed 'Home, Daily asthma log, Air quality, My plan, Trends, Appointments, Educational material, Messages, and Notifications') with the App during Weeks 9 to 12.
Number of Days Participants Accessed the AMAZE™ App (Weeks 13 to 16)	Weeks 13 to 16	Participant App usage was measured as the number of days the participant engaged (ie., participants accessed 'Home, Daily asthma log, Air quality, My plan, Trends, Appointments, Educational material, Messages, and Notifications') with the App during Weeks 13 to 16.
Number of Days Participants Accessed the AMAZE™ App (Weeks 17 to 20)	Weeks 17 to 20	Participant App usage was measured as the number of days the participant engaged (ie., participants accessed 'Home, Daily asthma log, Air quality, My plan, Trends, Appointments, Educational material, Messages, and Notifications') with the App during Weeks 17 to 20.
Number of Days Participants Accessed the AMAZE™ App (Weeks 21 to 24)	Weeks 21 to 24	Participant App usage was measured as the number of days the participant engaged (ie., participants accessed 'Home, Daily asthma log, Air quality, My plan, Trends, Appointments, Educational material, Messages, and Notifications') with the App during Weeks 21 to 24.
Number of Days Clinical Site Staff Accessed the AMAZE™ Dashboard (Weeks 1 to 4)	Weeks 1 to 4	Clinician dashboard usage was measured as the mean number of days that the clinical site staff accessed the AMAZE™ dashboard during Weeks 1 to 4.
Number of Days Clinical Site Staff Accessed the AMAZE™ Dashboard (Weeks 5 to 8)	Weeks 5 to 8	Clinician dashboard usage was measured as the mean number of days that the clinical site staff accessed the AMAZE™ dashboard during Weeks 5 to 8.
Number of Days Clinical Site Staff Accessed the AMAZE™ Dashboard (Weeks 9 to 12)	Weeks 9 to 12	Clinician dashboard usage was measured as the mean number of days that the clinical site staff accessed the AMAZE™ dashboard during Weeks 9 to 12.
Number of Days Clinical Site Staff Accessed the AMAZE™ Dashboard (Weeks 13 to 16)	Weeks 13 to 16	Clinician dashboard usage was measured as the mean number of days that the clinical site staff accessed the AMAZE™ dashboard during Weeks 13 to 16.
Number of Days Clinical Site Staff Accessed the AMAZE™ Dashboard (Weeks 17 to 20)	Weeks 17 to 20	Clinician dashboard usage was measured as the mean number of days that the clinical site staff accessed the AMAZE™ dashboard during Weeks 17 to 20.
Number of Days Clinical Site Staff Accessed the AMAZE™ Dashboard (Weeks 21 to 24)	Weeks 21 to 24	Clinician dashboard usage was measured as the mean number of days that the clinical site staff accessed the AMAZE™ dashboard during Weeks 21 to 24.
Number of Participants Engaged in Agreement of Visit Survey Item 9 (Weeks 1 to 4)	Weeks 1 to 4	Visit Survey Item 9 was 'The visit helped avoid an emergency room (ER) or urgent care center visit or hospitalization.' Visit surveys were completed throughout the study whenever a participant completed an asthma-related clinic visit. Number of participants engaged in agreement of Visit Survey Item 9 as 'High' (ie., 5-7 days per week per month) and 'Very low' (ie., less than one day per week per month) are reported.
Number of Participants Engaged in Agreement of Visit Survey Item 9 (Weeks 5 to 8)	Weeks 5 to 8	Visit Survey Item 9 was 'The visit helped avoid an ER or urgent care center visit or hospitalization.' Visit surveys were completed throughout the study whenever a participant completed an asthma-related clinic visit. Number of participants engaged in agreement of Visit Survey Item 9 as 'High' (ie., 5-7 days per week per month) and 'Very low' (ie., less than one day per week per month) are reported.
Number of Participants Engaged in Agreement of Visit Survey Item 9 (Weeks 9 to 12)	Weeks 9 to 12	Visit Survey Item 9 was 'The visit helped avoid an ER or urgent care center visit or hospitalization.' Visit surveys were completed throughout the study whenever a participant completed an asthma-related clinic visit. Number of participants engaged in agreement of Visit Survey Item 9 as 'High' (ie., 5-7 days per week per month) and 'Very low' (ie., less than one day per week per month) are reported.
Number of Participants Engaged in Agreement of Visit Survey Item 9 (Weeks 13 to 16)	Weeks 13 to 16	Visit Survey Item 9 was 'The visit helped avoid an ER or urgent care center visit or hospitalization.' Visit surveys were completed throughout the study whenever a participant completed an asthma-related clinic visit. Number of participants engaged in agreement of Visit Survey Item 9 as 'High' (ie., 5-7 days per week per month) and 'Very low' (ie., less than one day per week per month) are reported.
Number of Participants Engaged in Agreement of Visit Survey Item 9 (Weeks 17 to 20)	Weeks 17 to 20	Visit Survey Item 9 was 'The visit helped avoid an ER or urgent care center visit or hospitalization.' Visit surveys were completed throughout the study whenever a participant completed an asthma-related clinic visit. Number of participants engaged in agreement of Visit Survey Item 9 as 'High' (ie., 5-7 days per week per month) and 'Very low' (ie., less than one day per week per month) are reported.
Number of Participants Engaged in Agreement of Visit Survey Item 9 (Weeks 21 to 24)	Weeks 21 to 24	Visit Survey Item 9 was 'The visit helped avoid an ER or urgent care center visit or hospitalization.' Visit surveys were completed throughout the study whenever a participant completed an asthma-related clinic visit. Number of participants engaged in agreement of Visit Survey Item 9 as 'High' (ie., 5-7 days per week per month) and 'Very low' (ie., less than one day per week per month) are reported.
Evaluate Participant Satisfaction With the AMAZE™ App (End of Study)	End of Study (Month 6)	Satisfaction with the AMAZE™ App features was measured by the number of participants who reported satisfaction on parameters of 'Very unsatisfied, Unsatisfied, Neutral, Satisfied, and Very satisfied'.
Emergency Room Visits, Urgent Care Center Visits, or Hospitalization Avoidance (End of Study)	End of Study (Month 6)	The impact of AMAZE™ on ER, urgent care center visits, and hospitalizations was measured as the number of participants who reported "agree" or "strongly agree" with the question 'Since the start of the study, use of the AMAZE™ App helped me avoid ER or urgent care center visits or hospitalizations.' from the participant visit experience survey.
Impact of AMAZE™ App on Participants Clinic Visits	Day 1 through End of Study (Month 6)	Visit Survey Item 9 was 'The visit helped avoid an ER or urgent care center visit or hospitalization.' The impact of AMAZE™ on participant visits was measured as the number of participants who selected "agree" or "strongly agree" in response to the 9-items in the participant visit experience survey.
Participant Perception of Appointment Discussions and Taking Part in Asthma Decisions (End of Study)	End of Study (Month 6)	The impact of AMAZE™ on improved participant communication with their healthcare provider was measured as the number of participants who reported "agree" or "strongly agree" with the questions "The app helped me discuss my asthma with my healthcare providers during my most recent visit?", "App helped the appointment with my doctor go more smoothly?" and "I was included in making decisions about my asthma treatment during my most recent visit?" on the participant visit experience survey.
Patient Satisfaction Questionnaire-18 Subscale Scores (End of Study)	End of study (Month 6)	Participant satisfaction with their healthcare experience was evaluated using the PSQ-18 items with subscale scores of 'General satisfaction, Technical quality, Interpersonal manner, Communication, Financial aspects, Time spent with doctor, Accessibility and convenience' at End of Study (Month 6). The PSQ-18 scores ranges from 1 to 5 and a higher score indicates greater satisfaction.
Patient-Reported System Usability Scale (SUS) (Month 1)	Month 1	The usability of the AMAZE™ App was measured by the number of participants who rated the app as 'excellent, good, okay, poor, awful or skipped to report' at Month 1.
Patient-Reported SUS (End of Study)	End of Study (Month 6)	The usability of the AMAZE™ App was measured by the number of participants who rated the app as 'excellent, good, okay, poor, awful or skipped to report' at End of Study (Month 6).
Clinical Site Staff-Reported SUS (Month 1)	Month 1	The usability of the AMAZE™ dashboard was measured by the number of clinical staff who rated the App as 'excellent, good, okay, poor, awful or skipped to report' at Month 1.
Clinical Site Staff-Reported SUS (End of Study)	End of Study (Month 6)	The usability of the AMAZE™ dashboard was measured by the number of clinical staff who rated the App as 'excellent, good, okay, poor, awful or skipped to report' at End of Study (Month 6).
Evaluate Ease of Implementation of AMAZE™ App in Clinical Setting (End of Study)	End of Study (Month 6)	The ease of implementation of AMAZE™ was measured by the number of clinical staff who reported "very easy" or "somewhat easy" to the question "How would you rate the overall ease of implementing AMAZE™ on a platform into your clinical practice?" in the post-study survey at End of Study (Month 6).
Evaluate Impact of AMAZE™ App on Managing Participants (End of Study)	End of Study (Month 6)	The impact of AMAZE™ on managing participants was measured by the number of clinical staff who reported "moderately" or "very well" to the question "Did the AMAZE™ help you manage your participants?" in the post-study survey at End of Study (Month 6).
Evaluate Perceived Benefit of AMAZE™ App in Clinical Setting (End of Study)	End of Study (Month 6)	The perceived benefit of AMAZE™ was evaluated by the number of clinical staff who endorsed different perceived benefits as "Ability to track symptoms, Ability to track asthma triggers, Ability to track reliever medication use, Ability track ER visits/ hospitalizations, and Integration of AMAZE™ platform with electronic health records" based on the item "What did you find the most useful about the AMAZE™ platform?" in the post-study survey at End of Study (Month 6).
Evaluate Perceived Disadvantages of AMAZE™ in Clinical Setting (End of Study)	End of Study (Month 6).	The perceived disadvantages of AMAZE™ were evaluated by the number of clinical site staff who endorsed different perceived disadvantages as "Ability to track air flow measurements, Participant-health care provides (HCP) messaging feature, Ability to assign another healthcare provider to a participant, Ability to track level of impairment through Asthma Control Test (ACT™) scores" based on the question "What did you find the least useful or cumbersome about the AMAZE™ platform?" in the post-study survey at End of Study (Month 6).